1/5
Favipiravir Avigan for Conoravirus Medicine Cure Raw Material图1Favipiravir Avigan for Conoravirus Medicine Cure Raw Material图2

Favipiravir Avigan for Conoravirus Medicine Cure Raw Material

$0.00
FOB Price:
Negotiable | Get Latest Price
Order Quantity:
1 Set / Sets
Supply Ability:
1000 Set / Sets per Month
Port:
shanghai
Payment Terms:
T/T L/C D/P D/A Credit Card PayPal Cash Escrow Other
Delivery Detail:
5 days
Hot in store
Product Details
Product Name: Favipiravir Avigan for Conoravirus Medicine Cure Raw Material Purity: >99% State: Solid Suitable for: Elderly, Children, Adult Certification: ISO 9001 Customized: Non-Customized Powder: Yes Origin: China Product Description Raw Material Favipiravir CAS 259793-96-9 T-705 Avigan for Conoravirus Medicine Cure Product nameFavipiravirCAS NO.259793-96-9CategoryPharmaceutical Raw Materials,Active Pharmaceutical Ingredients,Bulk Drugs,Fine Chemicals.Purity99%Appearanceyellow powderShelf life2 yearsUsageFavipiravir is an antiviral drug.StorageFavipiravir should be stored in a well-closed container at low temperature, keep away from moisture, heat and light.NoteFavipiravir for R&D use only.Favipiravir,alsoknownasT1106,itisapyrazinecarboxamidederivative.Favipiravirisactiveagainstinfluenzaviruses,WestNilevirus,yellowfevervirus,footandmouthdiseasevirusaswellasotherflaviviruses,arenaviruses,bunyavirusesandalphaviruses.ActivityagainstenterovirusesandRiftValleyfevervirushasalsobeendemonstrated.ThemechanismofitsactionsisthoughttoberelatedtotheselectiveinhibitionofviralRNAdependentRNApolymerase.FavipiravirdoesnotinhibitRNAorDNAsynthesisinmammaliancellsandisnottoxictothemIn2014,favipiravirwasapprovedinJapanforstockpilingagainstinfluenzapandemics.EbolavirusdiseaseThedrugappearstobeeffectiveinamousemodelofEbolavirusdisease,butitsefficacyagainsthumanEbolainfectionisunproved.Duringthe2014WestAfricaEbolavirusoutbreak,itwasreportedthataFrenchnursewhocontractedEbolawhilevolunteeringforMSFinLiberiarecoveredafterreceivingacourseoffavipiravir.AclinicaltrialinvestigatingtheuseoffavipiraviragainstEbolavirusdiseasewasstartedinGuéckédou,Guinea,duringDecember2014.PreliminaryresultsshowedadecreaseinmortalityrateinpatientswithlowtomoderatelevelsofEbolavirusintheblood,butnoeffectonpatientswithhighlevelsofthevirus,agroupatahigherriskofdeath.
Contact with Supplier

Inquiry title*

main content*

company

Name*

Telephone*

Email*

QQ

Ali Wangwang

Recommend product